Baseline clinical and echocardiographic parameters
| All patients | Clinical event | p Value | ||
| No (n = 97) | Yes (n = 70) | |||
| Age | 64.6±11.8 | 63.3±11.5 | 66.5±11.9 | 0.092 |
| Sex (male, %) | 65.3 | 67.0 | 62.9 | 0.623 |
| Surface ECG | ||||
| QRS duration | 112.5±27.1 | 108.2±23.8 | 118.5±30.2 | 0.019 |
| LBBB (%) | 16.2 | 12.4 | 21.4 | 0.138 |
| Ischaemic origin | 98 (58.7%) | 48 (49.5%) | 50 (71.4%) | 0.007 |
| Diabetes mellitus (%) | 39.2 | 33.3 | 47.9 | 0.079 |
| Creatinine (mg/dl) | 1.78±1.78 | 1.44±1.42 | 2.19±2.07 | 0.010 |
| Drugs | ||||
| β Blocker (%) | 79 | 85.3 | 72.9 | 0.075 |
| Dose of carvedilol, (mg) | 30.7±13.3 | 33.3±13.5 | 27.3±12.4 | 0.022 |
| ACEI or ARB (%) | 92.8 | 95.8 | 90.0 | 0.205 |
| 86.2 | 84.4 | 90.0 | 0.211 | |
| LV dimension (mm) | ||||
| End-diastole | 61.0±8.2 | 60.7±6.9 | 61.3±9.8 | 0.653 |
| End-systole | 49.5±9.8 | 49.4±8.7 | 49.5±11.1 | 0.966 |
| LV volume (ml) | ||||
| End-diastole | 145.5±55.8 | 139.4±52.2 | 154.0±59.7 | 0.103 |
| End-systole | 101.8±47.4 | 102.8±42.1 | 115.5±53.2 | 0.101 |
| LV ejection fraction (%) | 26.8±6.5 | 27.2±6.5 | 26.3±6.3 | 0.373 |
| Mitral regurgitation (%) | 0.032 | |||
| Mild | 46% | 51.1% | 39.1% | |
| Moderate | 36.8% | 38.3% | 34.8% | |
| Severe | 17.2% | 10.6% | 26.1% | |
| Ts−l (ms) | 64.2±48.2 | 55.0±42.5 | 76.3±52.8 | 0.005 |
Mitral regurgitation: mild (regurgitation orifice area ≤0.2 cm2), moderate (0.2–0.39 cm2), and severe (≥0.4 cm2).
ACEI, ACE inhibitor; ARB, angiotensin receptor blocker; LBBB, left bundle branch block; LV, left ventricular; Ts–l, time difference between the septal and lateral wall.